top of page

7 Hills Pharma's Milestone Achievement in Non-dilutive Funding

7 Hills Pharma ("7HP") has made remarkable strides in the biopharmaceutical sector, recently surpassing the $25 million milestone in non-dilutive funding. A significant portion of this funding comes from a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). This grant will facilitate the advancement of 7HP349, an innovative oral selective integrin activator, into a Phase 1b/2a clinical trial.


The Need for Novel Therapies

The global market for immune checkpoint inhibitors like KEYTRUDA® (pembrolizumab) and OPDIVO® (nivolumab) has skyrocketed, with annual sales exceeding $30 billion. However, these therapies fail to elicit a response in up to 90% of patients with solid tumors. This has left a gaping void in the market, one which 7HP's alintegimod, also known as 7HP349, aims to fill by offering a unique mechanism to safely overcome resistance to a wide array of immunotherapies.

The Promise of 7HP349

Alintegimod or 7HP349, is the lead, clinical-stage integrin agonist from 7 Hills Pharma. This first-in-class, orally-delivered small molecule selectively activates integrins LFA-1 and VLA-4 to enhance antigen-specific immune responses. It has shown promising results in preclinical models, improving the effectiveness of numerous immune checkpoint inhibitors and infectious disease vaccines.

In a Phase 1 clinical trial, alintegimod demonstrated oral bioavailability and a clean safety profile at exposures surpassing therapeutic levels. This unique mechanism of action of alintegimod aims to augment T-cell activation in patients with checkpoint blockade-resistant tumors, offering them a new treatment option without any additional toxicities.

CPRIT's Support for Innovation

CPRIT's grant is a testament to its commitment to fostering early-stage talent and technology in Texas. This support is vital for enabling groundbreaking innovations like alintegimod to thrive in the underserved regional venture capital ecosystem, attracting follow-on investment and strategic partnerships.

7 Hills Pharma's Vision

7 Hills Pharma is a clinical-stage immunotherapy company that develops a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Their compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize cell-cell interactions required for an effective immune response.

Future Prospects

With the new CPRIT funding, 7 Hills Pharma anticipates significant advancements in the development of alintegimod. This is likely to attract further investments and strategic partnerships, further propelling the company forward in its mission to deliver the full promise of immunotherapy.

Conclusion

The journey of 7 Hills Pharma in the immunotherapy landscape is laudable. With its innovative approach and strategic partnerships, the company is poised to make a significant impact on the treatment of solid tumors and prevention of infectious diseases. The recent milestone in non-d

3 views

Recent Posts

See All

Comments


bottom of page